Summary
According to APO Research, The global Peptide Antibiotics market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Peptide Antibiotics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Peptide Antibiotics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Peptide Antibiotics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Peptide Antibiotics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Peptide Antibiotics include AMP Therapeutics, Hospira, Kasten, Madam Therapeutics, Pacgen Life Science Corporation, Phosphagenics, Savara Pharmaceuticals, Theravance and Vicuron Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Peptide Antibiotics, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Peptide Antibiotics, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide Antibiotics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Peptide Antibiotics sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Peptide Antibiotics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Peptide Antibiotics sales, projected growth trends, production technology, application and end-user industry.
Peptide Antibiotics Segment by Company
AMP Therapeutics
Hospira
Kasten
Madam Therapeutics
Pacgen Life Science Corporation
Phosphagenics
Savara Pharmaceuticals
Theravance
Vicuron Pharmaceuticals
GlaxoSmithKline
Pfizer
Eli Lilly
Novartis
Peptide Antibiotics Segment by Type
Ribosomal Synthesized Peptide Antibiotics
Non-Ribosomally Synthesized Peptide Antibiotics
Peptide Antibiotics Segment by Application
Pharma & Healthcare
Food Industry
Commodities
Other
Peptide Antibiotics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Antibiotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Antibiotics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Antibiotics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Peptide Antibiotics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Antibiotics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Peptide Antibiotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Peptide Antibiotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
- Market Overview
- Product Definition
- Global Peptide Antibiotics Market Size, 2020 VS 2024 VS 2031
- Global Peptide Antibiotics Market Size Estimates and Forecasts (2020-2031)
- Global Peptide Antibiotics Sales Estimates and Forecasts (2020-2031)
- Global Peptide Antibiotics Market Average Price (2020-2031)
- Assumptions and Limitations
- Study Goals and Objectives
- Global Peptide Antibiotics Market Dynamics
- Peptide Antibiotics Industry Trends
- Peptide Antibiotics Industry Drivers
- Peptide Antibiotics Industry Opportunities and Challenges
- Peptide Antibiotics Industry Restraints
- Peptide Antibiotics Market by Manufacturers
- Global Peptide Antibiotics Revenue by Manufacturers (2020-2025)
- Global Peptide Antibiotics Sales by Manufacturers (2020-2025)
- Global Peptide Antibiotics Average Sales Price by Manufacturers (2020-2025)
- Global Peptide Antibiotics Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- Global Peptide Antibiotics Key Manufacturers Manufacturing Sites & Headquarters
- Global Peptide Antibiotics Manufacturers, Product Type & Application
- Global Peptide Antibiotics Manufacturers Establishment Date
- Market Competitive Analysis
- Global Peptide Antibiotics Market CR5 and HHI
- Global Top 5 and 10 Peptide Antibiotics Players Market Share by Revenue in 2024
- 2024 Peptide Antibiotics Tier 1, Tier 2, and Tier 3
- Peptide Antibiotics Market by Type
- Peptide Antibiotics Type Introduction
- Ribosomal Synthesized Peptide Antibiotics
- Non-Ribosomally Synthesized Peptide Antibiotics
- Global Peptide Antibiotics Sales by Type
- Global Peptide Antibiotics Sales by Type (2020 VS 2024 VS 2031)
- Global Peptide Antibiotics Sales by Type (2020-2031)
- Global Peptide Antibiotics Sales Market Share by Type (2020-2031)
- Global Peptide Antibiotics Revenue by Type
- Global Peptide Antibiotics Revenue by Type (2020 VS 2024 VS 2031)
- Global Peptide Antibiotics Revenue by Type (2020-2031)
- Global Peptide Antibiotics Revenue Market Share by Type (2020-2031)
- Peptide Antibiotics Type Introduction
- Peptide Antibiotics Market by Application
- Peptide Antibiotics Application Introduction
- Pharma & Healthcare
- Food Industry
- Commodities
- Other
- Global Peptide Antibiotics Sales by Application
- Global Peptide Antibiotics Sales by Application (2020 VS 2024 VS 2031)
- Global Peptide Antibiotics Sales by Application (2020-2031)
- Global Peptide Antibiotics Sales Market Share by Application (2020-2031)
- Global Peptide Antibiotics Revenue by Application
- Global Peptide Antibiotics Revenue by Application (2020 VS 2024 VS 2031)
- Global Peptide Antibiotics Revenue by Application (2020-2031)
- Global Peptide Antibiotics Revenue Market Share by Application (2020-2031)
- Peptide Antibiotics Application Introduction
- Global Peptide Antibiotics Sales by Region
- Global Peptide Antibiotics Sales by Region: 2020 VS 2024 VS 2031
- Global Peptide Antibiotics Sales by Region (2020-2031)
- Global Peptide Antibiotics Sales by Region (2020-2025)
- Global Peptide Antibiotics Sales Forecasted by Region (2025-2030)
- North America
- North America Peptide Antibiotics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- North America Peptide Antibiotics Sales by Country (2020-2031)
- U.S.
- Canada
- Mexico
- Europe
- Europe Peptide Antibiotics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- Europe Peptide Antibiotics Sales by Country (2020-2031)
- Germany
- France
- U.K.
- Italy
- Netherlands
- Asia Pacific
- Asia Pacific Peptide Antibiotics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- Asia Pacific Peptide Antibiotics Sales by Country (2020-2031)
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- South America, Middle East and Africa
- South America, Middle East and Africa Peptide Antibiotics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- South America, Middle East and Africa Peptide Antibiotics Sales by Country (2020-2031)
- Brazil
- South Africa
- Saudi Arabia
- Turkey
- Argentina
- UAE
- Egypt
- Chile
- Global Peptide Antibiotics Revenue by Region
- Global Peptide Antibiotics Revenue by Region
- Global Peptide Antibiotics Revenue by Region: 2020 VS 2024 VS 2031
- Global Peptide Antibiotics Revenue by Region (2020-2025)
- Global Peptide Antibiotics Revenue by Region (2026-2031)
- Global Peptide Antibiotics Revenue Market Share by Region (2020-2031)
- North America
- North America Peptide Antibiotics Revenue (2020-2031)
- North America Peptide Antibiotics Revenue Share by Country: 2020 VS 2024 VS 2031
- Europe
- Europe Peptide Antibiotics Revenue (2020-2031)
- Europe Peptide Antibiotics Revenue Share by Country: 2020 VS 2024 VS 2031
- Asia-Pacific
- Asia-Pacific Peptide Antibiotics Revenue (2020-2031)
- Asia-Pacific Peptide Antibiotics Revenue Share by Country: 2020 VS 2024 VS 2031
- South America, Middle East and Africa
- South America, Middle East and Africa Peptide Antibiotics Revenue (2020-2031)
- South America, Middle East and Africa Peptide Antibiotics Revenue Share by Country: 2020 VS 2024 VS 2031
- Global Peptide Antibiotics Revenue by Region
- Company Profiles
- AMP Therapeutics
- AMP Therapeutics Comapny Information
- AMP Therapeutics Business Overview
- AMP Therapeutics Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
- AMP Therapeutics Peptide Antibiotics Product Portfolio
- AMP Therapeutics Recent Developments
- Hospira
- Hospira Comapny Information
- Hospira Business Overview
- Hospira Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
- Hospira Peptide Antibiotics Product Portfolio
- Hospira Recent Developments
- Kasten
- Kasten Comapny Information
- Kasten Business Overview
- Kasten Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
- Kasten Peptide Antibiotics Product Portfolio
- Kasten Recent Developments
- Madam Therapeutics
- Madam Therapeutics Comapny Information
- Madam Therapeutics Business Overview
- Madam Therapeutics Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
- Madam Therapeutics Peptide Antibiotics Product Portfolio
- Madam Therapeutics Recent Developments
- Pacgen Life Science Corporation
- Pacgen Life Science Corporation Comapny Information
- Pacgen Life Science Corporation Business Overview
- Pacgen Life Science Corporation Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
- Pacgen Life Science Corporation Peptide Antibiotics Product Portfolio
- Pacgen Life Science Corporation Recent Developments
- Phosphagenics
- Phosphagenics Comapny Information
- Phosphagenics Business Overview
- Phosphagenics Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
- Phosphagenics Peptide Antibiotics Product Portfolio
- Phosphagenics Recent Developments
- Savara Pharmaceuticals
- Savara Pharmaceuticals Comapny Information
- Savara Pharmaceuticals Business Overview
- Savara Pharmaceuticals Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
- Savara Pharmaceuticals Peptide Antibiotics Product Portfolio
- Savara Pharmaceuticals Recent Developments
- Theravance
- Theravance Comapny Information
- Theravance Business Overview
- Theravance Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
- Theravance Peptide Antibiotics Product Portfolio
- Theravance Recent Developments
- Vicuron Pharmaceuticals
- Vicuron Pharmaceuticals Comapny Information
- Vicuron Pharmaceuticals Business Overview
- Vicuron Pharmaceuticals Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
- Vicuron Pharmaceuticals Peptide Antibiotics Product Portfolio
- Vicuron Pharmaceuticals Recent Developments
- GlaxoSmithKline
- GlaxoSmithKline Comapny Information
- GlaxoSmithKline Business Overview
- GlaxoSmithKline Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
- GlaxoSmithKline Peptide Antibiotics Product Portfolio
- GlaxoSmithKline Recent Developments
- Pfizer
- Pfizer Comapny Information
- Pfizer Business Overview
- Pfizer Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
- Pfizer Peptide Antibiotics Product Portfolio
- Pfizer Recent Developments
- Eli Lilly
- Eli Lilly Comapny Information
- Eli Lilly Business Overview
- Eli Lilly Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
- Eli Lilly Peptide Antibiotics Product Portfolio
- Eli Lilly Recent Developments
- Novartis
- Novartis Comapny Information
- Novartis Business Overview
- Novartis Peptide Antibiotics Sales, Price, Revenue and Gross Margin (2020-2025)
- Novartis Peptide Antibiotics Product Portfolio
- Novartis Recent Developments
- AMP Therapeutics
- Value Chain and Sales Channels Analysis
- Peptide Antibiotics Value Chain Analysis
- Peptide Antibiotics Key Raw Materials
- Raw Materials Key Suppliers
- Manufacturing Cost Structure
- Peptide Antibiotics Production Mode & Process
- Peptide Antibiotics Sales Channels Analysis
- Direct Comparison with Distribution Share
- Peptide Antibiotics Distributors
- Peptide Antibiotics Customers
- Peptide Antibiotics Value Chain Analysis
- Concluding Insights
- Appendix
- Reasons for Doing This Study
- Research Methodology
- Research Process
- Authors List of This Report
- Data Source
- Secondary Sources
- Primary Sources
- Disclaimer
List of Tables
Table 1 | :Peptide Antibiotics Industry Trends |
Table 2 | :Peptide Antibiotics Industry Drivers |
Table 3 | :Peptide Antibiotics Industry Opportunities and Challenges |
Table 4 | :Peptide Antibiotics Industry Restraints |
Table 5 | :Global Peptide Antibiotics Revenue by Manufacturers (US$ Million) & (2020-2025) |
Table 6 | :Global Peptide Antibiotics Revenue Market Share by Manufacturers (2020-2025) |
Table 7 | :Global Peptide Antibiotics Sales by Manufacturers (Tons) & (2020-2025) |
Table 8 | :Global Peptide Antibiotics Sales Market Share by Manufacturers |
Table 9 | :Global Peptide Antibiotics Average Sales Price (US$/Ton) of Manufacturers (2020-2025) |
Table 10 | :Global Peptide Antibiotics Industry Manufacturers Ranking, 2023 VS 2024 VS 2025 |
Table 11 | :Global Peptide Antibiotics Key Manufacturers Manufacturing Sites & Headquarters |
Table 12 | :Global Peptide Antibiotics Manufacturers, Product Type & Application |
Table 13 | :Global Peptide Antibiotics Manufacturers Establishment Date |
Table 14 | :Global Manufacturers Market Concentration Ratio (CR5 and HHI) |
Table 15 | :Global Peptide Antibiotics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2024) |
Table 16 | :Major Manufacturers of Ribosomal Synthesized Peptide Antibiotics |
Table 17 | :Major Manufacturers of Non-Ribosomally Synthesized Peptide Antibiotics |
Table 18 | :Global Peptide Antibiotics Sales by Type 2020 VS 2024 VS 2031 (Tons) |
Table 19 | :Global Peptide Antibiotics Sales by Type (2020-2025) & (Tons) |
Table 20 | :Global Peptide Antibiotics Sales by Type (2026-2031) & (Tons) |
Table 21 | :Global Peptide Antibiotics Sales Market Share by Type (2020-2025) |
Table 22 | :Global Peptide Antibiotics Sales Market Share by Type (2026-2031) |
Table 23 | :Global Peptide Antibiotics Revenue by Type 2020 VS 2024 VS 2031 (Tons) |
Table 24 | :Global Peptide Antibiotics Revenue by Type (2020-2025) & (Tons) |
Table 25 | :Global Peptide Antibiotics Revenue by Type (2026-2031) & (Tons) |
Table 26 | :Global Peptide Antibiotics Revenue Market Share by Type (2020-2025) |
Table 27 | :Global Peptide Antibiotics Revenue Market Share by Type (2026-2031) |
Table 28 | :Major Manufacturers of Pharma & Healthcare |
Table 29 | :Major Manufacturers of Food Industry |
Table 30 | :Major Manufacturers of Commodities |
Table 31 | :Major Manufacturers of Other |
Table 32 | :Global Peptide Antibiotics Sales by Application 2020 VS 2024 VS 2031 (Tons) |
Table 33 | :Global Peptide Antibiotics Sales by Application (2020-2025) & (Tons) |
Table 34 | :Global Peptide Antibiotics Sales by Application (2026-2031) & (Tons) |
Table 35 | :Global Peptide Antibiotics Sales Market Share by Application (2020-2025) |
Table 36 | :Global Peptide Antibiotics Sales Market Share by Application (2026-2031) |
Table 37 | :Global Peptide Antibiotics Revenue by Application 2020 VS 2024 VS 2031 (Tons) |
Table 38 | :Global Peptide Antibiotics Revenue by Application (2020-2025) & (Tons) |
Table 39 | :Global Peptide Antibiotics Revenue by Application (2026-2031) & (Tons) |
Table 40 | :Global Peptide Antibiotics Revenue Market Share by Application (2020-2025) |
Table 41 | :Global Peptide Antibiotics Revenue Market Share by Application (2026-2031) |
Table 42 | :Global Peptide Antibiotics Sales by Region: 2020 VS 2024 VS 2031 (Tons) |
Table 43 | :Global Peptide Antibiotics Sales by Region (2020-2025) & (Tons) |
Table 44 | :Global Peptide Antibiotics Sales Market Share by Region (2020-2025) |
Table 45 | :Global Peptide Antibiotics Sales Forecasted by Region (2026-2031) & (Tons) |
Table 46 | :Global Peptide Antibiotics Sales Forecasted Market Share by Region (2026-2031) |
Table 47 | :North America Peptide Antibiotics Sales Growth Rate by Country: 2020 VS 2024 VS 2031 (Tons) |
Table 48 | :North America Peptide Antibiotics Sales by Country (2020-2025) & (Tons) |
Table 49 | :North America Peptide Antibiotics Sales by Country (2026-2031) & (Tons) |
Table 50 | :Europe Peptide Antibiotics Sales Growth Rate by Country: 2020 VS 2024 VS 2031 (Tons) |
Table 51 | :Europe Peptide Antibiotics Sales by Country (2020-2025) & (Tons) |
Table 52 | :Europe Peptide Antibiotics Sales by Country (2026-2031) & (Tons) |
Table 53 | :Asia Pacific Peptide Antibiotics Sales Growth Rate by Country: 2020 VS 2024 VS 2031 (Tons) |
Table 54 | :Asia Pacific Peptide Antibiotics Sales by Country (2020-2025) & (Tons) |
Table 55 | :Asia Pacific Peptide Antibiotics Sales by Country (2026-2031) & (Tons) |
Table 56 | :South America, Middle East and Africa Peptide Antibiotics Sales Growth Rate by Country: 2020 VS 2024 VS 2031 (Tons) |
Table 57 | :South America, Middle East and Africa Peptide Antibiotics Sales by Country (2020-2025) & (Tons) |
Table 58 | :South America, Middle East and Africa Peptide Antibiotics Sales by Country (2026-2031) & (Tons) |
Table 59 | :Global Peptide Antibiotics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million) |
Table 60 | :Global Peptide Antibiotics Revenue by Region (2020-2025) & (US$ Million) |
Table 61 | :Global Peptide Antibiotics Revenue by Region (2026-2031) & (US$ Million) |
Table 62 | :Global Peptide Antibiotics Revenue Market Share by Region (2020-2025) |
Table 63 | :Global Peptide Antibiotics Revenue Market Share by Region (2026-2031) |
Table 64 | :AMP Therapeutics Company Information |
Table 65 | :AMP Therapeutics Business Overview |
Table 66 | :AMP Therapeutics Peptide Antibiotics Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 67 | :AMP Therapeutics Peptide Antibiotics Product Portfolio |
Table 68 | :AMP Therapeutics Recent Development |
Table 69 | :Hospira Company Information |
Table 70 | :Hospira Business Overview |
Table 71 | :Hospira Peptide Antibiotics Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 72 | :Hospira Peptide Antibiotics Product Portfolio |
Table 73 | :Hospira Recent Development |
Table 74 | :Kasten Company Information |
Table 75 | :Kasten Business Overview |
Table 76 | :Kasten Peptide Antibiotics Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 77 | :Kasten Peptide Antibiotics Product Portfolio |
Table 78 | :Kasten Recent Development |
Table 79 | :Madam Therapeutics Company Information |
Table 80 | :Madam Therapeutics Business Overview |
Table 81 | :Madam Therapeutics Peptide Antibiotics Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 82 | :Madam Therapeutics Peptide Antibiotics Product Portfolio |
Table 83 | :Madam Therapeutics Recent Development |
Table 84 | :Pacgen Life Science Corporation Company Information |
Table 85 | :Pacgen Life Science Corporation Business Overview |
Table 86 | :Pacgen Life Science Corporation Peptide Antibiotics Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 87 | :Pacgen Life Science Corporation Peptide Antibiotics Product Portfolio |
Table 88 | :Pacgen Life Science Corporation Recent Development |
Table 89 | :Phosphagenics Company Information |
Table 90 | :Phosphagenics Business Overview |
Table 91 | :Phosphagenics Peptide Antibiotics Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 92 | :Phosphagenics Peptide Antibiotics Product Portfolio |
Table 93 | :Phosphagenics Recent Development |
Table 94 | :Savara Pharmaceuticals Company Information |
Table 95 | :Savara Pharmaceuticals Business Overview |
Table 96 | :Savara Pharmaceuticals Peptide Antibiotics Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 97 | :Savara Pharmaceuticals Peptide Antibiotics Product Portfolio |
Table 98 | :Savara Pharmaceuticals Recent Development |
Table 99 | :Theravance Company Information |
Table 100 | :Theravance Business Overview |
Table 101 | :Theravance Peptide Antibiotics Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 102 | :Theravance Peptide Antibiotics Product Portfolio |
Table 103 | :Theravance Recent Development |
Table 104 | :Vicuron Pharmaceuticals Company Information |
Table 105 | :Vicuron Pharmaceuticals Business Overview |
Table 106 | :Vicuron Pharmaceuticals Peptide Antibiotics Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 107 | :Vicuron Pharmaceuticals Peptide Antibiotics Product Portfolio |
Table 108 | :Vicuron Pharmaceuticals Recent Development |
Table 109 | :GlaxoSmithKline Company Information |
Table 110 | :GlaxoSmithKline Business Overview |
Table 111 | :GlaxoSmithKline Peptide Antibiotics Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 112 | :GlaxoSmithKline Peptide Antibiotics Product Portfolio |
Table 113 | :GlaxoSmithKline Recent Development |
Table 114 | :Pfizer Company Information |
Table 115 | :Pfizer Business Overview |
Table 116 | :Pfizer Peptide Antibiotics Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 117 | :Pfizer Peptide Antibiotics Product Portfolio |
Table 118 | :Pfizer Recent Development |
Table 119 | :Eli Lilly Company Information |
Table 120 | :Eli Lilly Business Overview |
Table 121 | :Eli Lilly Peptide Antibiotics Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 122 | :Eli Lilly Peptide Antibiotics Product Portfolio |
Table 123 | :Eli Lilly Recent Development |
Table 124 | :Novartis Company Information |
Table 125 | :Novartis Business Overview |
Table 126 | :Novartis Peptide Antibiotics Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 127 | :Novartis Peptide Antibiotics Product Portfolio |
Table 128 | :Novartis Recent Development |
Table 129 | :Key Raw Materials |
Table 130 | :Raw Materials Key Suppliers |
Table 131 | :Peptide Antibiotics Distributors List |
Table 132 | :Peptide Antibiotics Customers List |
Table 133 | :Research Programs/Design for This Report |
Table 134 | :Authors List of This Report |
Table 135 | :Secondary Sources |
Table 136 | :Primary Sources |
List of Figures
Figure 1 | :Peptide Antibiotics Product Image |
Figure 2 | :Global Peptide Antibiotics Market Size (US$ Million), 2020 VS 2024 VS 2031 |
Figure 3 | :Global Peptide Antibiotics Market Size (2020-2031) & (US$ Million) |
Figure 4 | :Global Peptide Antibiotics Sales (2020-2031) & (Tons) |
Figure 5 | :Global Peptide Antibiotics Average Price (US$/Ton) & (2020-2031) |
Figure 6 | :Global Top 5 and 10 Peptide Antibiotics Players Market Share by Revenue in 2023 |
Figure 7 | :Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023 |
Figure 8 | :Ribosomal Synthesized Peptide Antibiotics Image |
Figure 9 | :Non-Ribosomally Synthesized Peptide Antibiotics Image |
Figure 10 | :Global Peptide Antibiotics Sales by Type (2020 VS 2024 VS 2031) & (Tons) |
Figure 11 | :Global Peptide Antibiotics Sales Market Share 2020 VS 2024 VS 2031 |
Figure 12 | :Global Peptide Antibiotics Sales Market Share by Type (2020-2031) |
Figure 13 | :Global Peptide Antibiotics Revenue by Type (2020 VS 2024 VS 2031) & (Tons) |
Figure 14 | :Global Peptide Antibiotics Revenue Market Share 2020 VS 2024 VS 2031 |
Figure 15 | :Global Peptide Antibiotics Revenue Market Share by Type (2020-2031) |
Figure 16 | :Pharma & Healthcare Image |
Figure 17 | :Food Industry Image |
Figure 18 | :Commodities Image |
Figure 19 | :Other Image |
Figure 20 | :Global Peptide Antibiotics Sales by Application (2020 VS 2024 VS 2031) & (Tons) |
Figure 21 | :Global Peptide Antibiotics Sales Market Share 2020 VS 2024 VS 2031 |
Figure 22 | :Global Peptide Antibiotics Sales Market Share by Application (2020-2031) |
Figure 23 | :Global Peptide Antibiotics Revenue by Application (2020 VS 2024 VS 2031) & (Tons) |
Figure 24 | :Global Peptide Antibiotics Revenue Market Share 2020 VS 2024 VS 2031 |
Figure 25 | :Global Peptide Antibiotics Revenue Market Share by Application (2020-2031) |
Figure 26 | :North America Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 27 | :North America Peptide Antibiotics Sales Market Share by Country (2020-2031) |
Figure 28 | :U.S. Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 29 | :Canada Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 30 | :Mexico Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 31 | :Europe Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 32 | :Europe Peptide Antibiotics Sales Market Share by Country (2020-2031) |
Figure 33 | :Germany Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 34 | :France Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 35 | :U.K. Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 36 | :Italy Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 37 | :Netherlands Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 38 | :Asia Pacific Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 39 | :Asia Pacific Peptide Antibiotics Sales Market Share by Country (2020-2031) |
Figure 40 | :China Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 41 | :Japan Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 42 | :South Korea Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 43 | :Southeast Asia Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 44 | :India Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 45 | :Australia Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 46 | :South America, Middle East and Africa Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 47 | :South America, Middle East and Africa Peptide Antibiotics Sales Market Share by Country (2020-2031) |
Figure 48 | :Brazil Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 49 | :South Africa Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 50 | :Saudi Arabia Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 51 | :Turkey Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 52 | :Argentina Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 53 | :UAE Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 54 | :Egypt Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 55 | :Chile Peptide Antibiotics Sales and Growth Rate (2020-2031) & (Tons) |
Figure 56 | :Global Peptide Antibiotics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million) |
Figure 57 | :Global Peptide Antibiotics Revenue Market Share by Region in Percentage: 2023 Versus 2030 |
Figure 58 | :North America Peptide Antibiotics Revenue (2020-2031) & (US$ Million) |
Figure 59 | :North America Peptide Antibiotics Revenue Share by Country: 2020 VS 2024 VS 2031 |
Figure 60 | :Europe Peptide Antibiotics Revenue (2020-2031) & (US$ Million) |
Figure 61 | :Europe Peptide Antibiotics Revenue Share by Country: 2020 VS 2024 VS 2031 |
Figure 62 | :Asia-Pacific Peptide Antibiotics Revenue (2020-2031) & (US$ Million) |
Figure 63 | :Asia-Pacific Peptide Antibiotics Revenue Share by Country: 2020 VS 2024 VS 2031 |
Figure 64 | :South America, Middle East and Africa Peptide Antibiotics Revenue (2020-2031) & (US$ Million) |
Figure 65 | :South America, Middle East and Africa Peptide Antibiotics Revenue Share by Country: 2020 VS 2024 VS 2031 |
Figure 66 | :Peptide Antibiotics Value Chain |
Figure 67 | :Manufacturing Cost Structure |
Figure 68 | :Peptide Antibiotics Production Mode & Process |
Figure 69 | :Direct Comparison with Distribution Share |
Figure 70 | :Distributors Profiles |
Figure 71 | :Years Considered |
Figure 72 | :Research Process |
Figure 73 | :Key Executives Interviewed |
Request a Sample
Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Pharma & Healthcare
Global Peptide Antibiotics Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Pages: 195
Complete Your Request
Customer reviews
- 0 out of 5
- 0 Reviews
5
4
3
2
1
No Rating Review Exist.
Write Review
Suggested Report
View MoreNo data found.